Envarsus, a novelty for transplant nephrologists: Observational retrospective study

The aim of this study was to evaluate the trough concentrations (Cptrough) and the tacrolimus dosage regimen after the conversion of Prograf or Advagraf to Envarsus (new pharmaceutical form with MeltDose technology that improves the absorption of fat-soluble drugs) in patients with stable renal tran...

Full description

Saved in:
Bibliographic Details
Published in:Nefrología 2019-09, Vol.39 (5), p.506-512
Main Authors: Franco, Antonio, Más-Serrano, Patricio, Balibrea, Noelia, Rodriguez, David, Javaloyes, Aurora, Díaz, Marcos, Gascón, Isabel, Ramon-Lopez, Amelia, Perez-Contreras, Javier, Selva, Juan, Nalda-Molina, Ricardo
Format: Article
Language:English
Subjects:
Advagraf
Bioavailability
Biodisponibilidad
Conversion
Conversión
Envarsus
Prograf
Renal transplant
Tacrolimus
Trasplante renal
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to evaluate the trough concentrations (Cptrough) and the tacrolimus dosage regimen after the conversion of Prograf or Advagraf to Envarsus (new pharmaceutical form with MeltDose technology that improves the absorption of fat-soluble drugs) in patients with stable renal transplantation, and their renal function. We selected stable renal transplant patients who were converted to Envarsus. Two periods were defined: Baseline and Conversion (Envarsus) and they were stratified according to the pharmaceutical form used in the Baseline period. Sixty-one patients were included (24 with Advagraf and 37 with Prograf), with an average age of 52years. The mean post-transplant time at the time of conversion to Envarsus was 76.3months and the mean follow-up in the Baseline and Conversion period was 10.1months and 11.6months, respectively. In the Prograf and Envarsus group, the Cptrough medians were 6.6 vs 6.4ng/ml (p=.636), with a mean daily dose that decreased significantly from 3mg to 2mg (p
ISSN:2013-2514
2013-2514
DOI:10.1016/j.nefroe.2018.11.020